MBRX — Moleculin Biotech Share News
0.000.00%
Last trade - 00:00Moleculin Biotech soars as FDA approves cancer drug trial
Brief: Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia
Brief: Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial
Brief: Moleculin Accelerates Planned Unblinded Data Readout For Miracle Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial To H2 2025
Brief: Moleculin Receives Institutional Review Board Approval For MIRACLE Phase 3 Pivotal Trial Of Annamycin In Combination With Cytarabine For The Treatment Of R/R Acute Myeloid Leukemia (AML)
U.S. RESEARCH ROUNDUP-Cable One, Neurogene, Topbuild
Moleculin Biotech Inc reports results for the quarter - Earnings Summary
Moleculin Biotech Inc expected to post a loss of $2.44 a share - Earnings Preview
Brief: Moleculin Announces Positive In Vivo Efficacy Data Of Annamycin In Orthotopic And Experimental Lung Metastatic Models Of Sarcoma
Brief: Moleculin Announces Closing Of Up To $16.5 Million Public Offering
Moleculin Biotech Inc expected to post a loss of $2.51 a share - Earnings Preview
Brief: Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial
Brief: Moleculin Biotech Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing
Brief: Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma
Moleculin Biotech Inc reports results for the quarter ended in January - Earnings Summary
Brief: Moleculin Announces U.S. Patent Issue Notification For Lipid-Based Delivery Technology For Annamycin
Moleculin Biotech Inc expected to post a loss of $3.53 a share - Earnings Preview
Brief: Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Brief: Moleculin Announces Formation Of Scientific Advisory Board To Support Development Of Annamycin